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Consequences of thrombosis, whether in the arterial or in the venous system, or in the left
atrium in patients with atrial fibrillation, are the most common causes of death. Therefore,
great attention is given to the prevention and treatment of thrombosis in the present. The
aim of this review article is to summarize the current knowledge on the laboratory and
clinical monitoring of the antithrombotic treatment.
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Consequences of thrombosis, whether in the arterial or in the
venous system, or in the left atrium in patients with atrial
fibrillation, are the most common causes of death. Therefore,
great attention is given to the prevention and treatment of
thrombosis in the present.
The aim of this review article is to summarize the current
knowledge on the laboratory and clinical monitoring of
antithrombotic (i.e. anticoagulant, antiplatelet and fibrinolytic)
treatment. For practical reasons, attention is limited to pro-
blems of anticoagulant and antiplatelet treatment monitoring.ed by Elsevier Urban & P2. Monitoring of anticoagulant treatment
The use of traditional anticoagulants is linked to strict
laboratory control of their efficiency in terms of both
insufficient and excessive dosage. The oldest drugs used
for anticoagulation – warfarin and heparin – have a very
narrow therapeutic window, and therefore their correct
dosing is closely linked with the need for accurate laboratory
control. In a case of inadequate dosage, the patient is in the
risk of thromboembolic complications, on the contrary, in a
case of higher levels may occur bleeding complications
(Fig. 1).artner Sp.z.o.o. on behalf of The Czech Society of Cardiology.
Table 1 – Target values for the evaluation of the
effectiveness of heparin.
aPTT 0.9–1.1 Reference value
aPTT 2–2.5 reference
value
Adequate treatment by unfractionated
heparin
Table 2 – The target values of the ACT for assessing the
effectiveness of heparin.
ACT 120–180s Normal values
ACT 200–350s Therapeutic values
Fig. 1 – Therapeutic range of warfarin. OR ¼ odds ratio,
INR ¼ international normalized ratio.
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oagulant. A number of studies showed a significant effect of
warfarin versus placebo in patients with atrial fibrillation, and
warfarin is effective in thromboembolic prevention also in
patients after valve replacement. Warfarin full dose was
significantly more effective in patients with atrial fibrillation
as compared to low-dose warfarin, aspirin and a combination
of aspirin with clopidogrel. Acetylsalicylic acid alone is not
effective either in preventing systemic embolism in patients
with atrial fibrillation or in preventing pulmonary embolism.
A combination of acetylsalicylic acid with clopidogrel is more
effective in preventing systemic embolism in atrial fibrillation
than acetylsalicylic acid alone, but significantly less effective
than warfarin [1]. The dosing of warfarin is very difficult and
is associated with the need for strict laboratory control by the
prothrombin test (PT), better expressed as International
Normalized Ratio (INR). Only two-thirds of the patients (and
in higher age groups, even less) are actually treated by
warfarin, the percentage of patients in a therapeutic range
of anticoagulation in the studies ACTIVE and SPORTIF was
only between 64% and 68%, and in the RE-LY study between 41%
and 77%. The problems of warfarin dosage are caused by the
presence of genetic polymorphisms, drug interactions or by the
frequent changes in the absorption due to food interactions.
From the above-mentioned reasons only half of the eligible
patients (and in higher age categories even less) actually receive
the drug [1]. The optimum range with maximum antithrombo-
tic effect and minimum bleeding complications is INR value
between 2.0 and 3.0 (Fig. 1). In the RE-LY study in warfarin open
branch was shown, that if the patients were divided into
quartiles according to the percentage results in the effective
range of anticoagulation, the mortality rate was directly related
to the degree of success of anticoagulant treatment.
From indirect inhibitors of thrombin (i.e. requiring the
presence of antithrombin) is still clinically used unfractionated
heparin (UFH). Monitoring of its effectiveness is carried out
using activated partial thromboplastin test (APTT) (partial
because of the absence of tissue factor in activation mixture).The time to blood coagulation is measured in oxalate or citrate
sample after adding phospholipid, an activator and calcium
(normally 25–39 s), effectivity of treatment is also expressed as
the ratio of the measured to control sample (Table 1).
In the GUSTO study with 29,656 patients, Granger et al. [2]
have shown that the values of APTT between 50 and 70 s are
associated with the lowest incidence of both ischemic and
bleeding complications.
Activated Clotting Time or Activated Coagulation Time (ACT) is
used for anticoagulation monitoring in the procedures requiring
administration of heparin, like cardiovascular surgery [3,4],
hemodialysis or coronary interventions [5] (Table 2). The test is
carried out directly at the operating theater or in the catheteriza-
tion laboratory and the results are available immediately.
The ACT is a quantitative test of coagulation based on the
same principle as APTT, the clotting is, however, initiated in
the whole blood using a contact activator without the
addition of phospholipids and calcium. It is used to monitor
the anticoagulant effect of high doses of heparin. Normal
values of the ACT are 80–140 s. The therapeutic range varies
according to the reason for heparin administration and is
200–350 s for coronary interventions and 400–500 s for cardi-
osurgical procedures. The ACT does not correlate with other
tests, but shows rather the degree of the prevention of
thrombus creation. The results are very sensitive to the
correct methodology, to the number and function of the
platelets, the degree of hypothermia, hemodilution and may
be also affected by some drugs, such as aprotinin. Thorough
compliance with the manufacturer’s instructions and the
proper methodology is important, the blood collection must
not be made from the entry sites, which have been
contaminated by heparin administration and the obtained
blood sample must be processed immediately – injected into
the test tube, the activator added and the timer activated.
Ferguson and the co-authors have demonstrated in the
early 1990s in the group of 1469 patients with PCI after
standard, weight-adjusted heparin dose that the complica-
tions were more common in patients with ACTo250 s than in
those with the ACT4300 [6,7]. ACT is also the appropriate test
to evaluate the anticoagulant activity of lowmolecular weight
heparin dalteparine after intravenous administration [8].
The EASY study evaluated the fate of the patients after PCI by
radial approach treated by combination of abciximab, clopido-
grel and aspirin. The final ACT of the 330 s was connected with
the smallest peri-PCI damage andwith the best prognosis during
Table 3 – The target values of the anti-Xa for assessing
the effectiveness of LMWH.
Anti-Xa
0.5–1.2 IU/ml Therapeutic value for b.i.d. administration
41.6 IU/ml Increased risk of bleeding
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The use of combination of antithrombotic treatment with the
active dose of newer antiplatelet drugs shows that for the
implementation of coronary interventionswith stenting it is safe
to administer even lower doses of heparin with target ACT 200 s,
or even just below this level [10]. Thismay not apply for STEMI or
PCI without stenting.
In another study evaluating major bleeding complications
after primary PCI for STEMI, a higher ACTwas associated with
an increased occurrence of bleeding (284763 vs. 248757 s,
P ¼ 0.007), multi-factorial analysis showed the value of the
ACT4250 s as being associated with significantly higher
incidence of bleeding and increased 6-month mortality [11].
Treatment by the low molecular weight heparins – LMWH
(enoxaparine, nadroparin, dalteparin, etc.) can be monitored
using anti-Xa activity (blood sample 3–4 h after administra-
tion of heparin) (Table 3).
The results of OASIS-5 study showed that the treatment by
enoxaparine can be associated with increased risk of bleed-
ing, especially for older patients and those with reduced
glomerular filtration rate. For enoxaparine administration it is
therefore appropriate to determine or calculate the glomer-
ular filtration rate (the calculation is available on www.
nephron.com) with the following enoxaparine dose adjustment: GF450 ml/min – dose adjusted according to the weight;
 GF 30–50 ml/min – reduced dose (appropriate anti-Xa
checks); GFo30 ml/min – adjust dose according to the anti-Xa (in
some countries LMWH contraindicated).
Therapeutic range of anti-Xa is between 0.5 and 1.2 (values
41.6 means an increased risk of bleeding).
From the newer anticoagulants – indirect factor Xa inhibitor,
fondaparinux (a synthetic pentasaccharide) has a more
favourable ratio of efficiency and bleeding risk than low
molecular weight heparins and does not need routine
monitoring, albeit it is possible tomeasure the level of anti-Xa.
Direct intravenous thrombin inhibitor bivaluridin has the
same efficiency and fewer bleeding complications in compar-
ison to the combination of heparin and abciximab (REPLACE-2
study with 6010 patients with elective PCI and ACUITY study
with 13,819 patients with medium and high risk acute
coronary syndrome). Its effectiveness can be monitored using
both ACT and APTT measurements.
One of the newer antithrombotic drug is dabigatran
etexilate, an oral, direct thrombin inhibitor, which is effective
after the conversion to its active form by serum esterase
(independent of cytochrome P-450). Dabigatran inhibits both
free thrombin and thrombin bound to fibrin and thrombin
induced platelet aggregation. Dabigatran etexilate – after oraladministration – is quickly absorbed and metabolized to
dabigatran in liver and plasma. Maximum plasma concentra-
tion is achieved in 1–2 h, with half-life 14–17 h, 80% is
eliminated by the kidneys. Dabigatran etexilate does not
have specific antidote, its half-life is short, however, and its
effects can be non-specifically reversed by higher doses of
PROTHROMPLEX TOTAL EA (includes the factor II, factor VII,
factor IX and factor X).
Dabigatran efficacy is influenced neither by drugs nor
dietary interactions nor by genetic polymorphisms. In the
prevention of thromboembolism in patients with atrial
fibrillation, the standard dose is twice daily 150 or 110 mg
and it is not necessary to monitor routinely the efficiency.
Dabigatran prolongs APTT (APTT is appropriate for the
correction of the supranormal values), APTT480 s at the
trough (immediately before the next dose) increases the risk
of bleeding). APTT is capable of only semiquantitative
assessment of the anticoagulant activity of direct thrombin
inhibitors (including dabigatran) and is not, however, suitable
for to its determination in high concentrations. The high
concentrations of direct thrombin inhibitors should be
assessed by determining the ECT or dilute TT (Hemoclots).
APTT rises linearly with plasmatic concentrations of dabiga-
tran with plateau at concentrations of Z200 ng/ml. After
supratherapeutic dose of dabigatran (400 mg t.i.d.), APTTwas
2–3fold both at the lowest and at the highest concentrations
of dabigatran (4400–500 ng/ml). During the chronic treatment
with dabigatran 150 mg b.i.d., the ratio is around 2. Twelve
hours after the last dose of dabigatran at the trough APTT is
around 1.5. APTT poorly reflects the range of concentrations,
which can occur in patients [12].
The effectiveness of direct thrombin inhibitors, including
dabigatran, can be determined by using the relatively
sensitive indicators like Ecarin Clotting Time (ECT) and
Thrombin Time (TT). More recently, HEMOCLOT test (CE
mark) was introduced for the evaluation of direct thrombin
inhibitors. The test is currently calibrated and approved for
hirudin, dabigatran and argatroban. The tests are based on
the chronometric method: provide the clotting time and after
appropriate calibration also plasmatic dabigatran concentra-
tion can be determined. Dabigatran does not affect the
prothrombin time (PT) or INR in clinically used doses.
Determination of INR in the case of warfarin is not
dependent on the time of blood sampling due to the
prolonged biological half-life (half-life of S-warfarin is
18–35 h and R-warfarin 20–70 h). On the other hand, the tests
to determine the anticoagulant activity of dabigatran should
be carried out at trough just before the intake of the following
dose due to its short biological half-life.
Thrombin time directly reflects the activity of thrombin
generation in plasma and is linearly proportional to plasma
concentrations of direct thrombin inhibitors. Its problem is
too high sensitivity, so due to the lack of standardization of
reagents in different laboratories, values in higher plasma
concentrations frequently exceed the maximum calibration
of the coagulometers.
Diluted thrombin time (Hemoclots)-Hemoclots Thrombin
Inhibitor assays (Hyphen BioMed, Neuville-sur-Oise, France)
allows quantitative determination of direct thrombin activity
in plasma. The test is based on the inhibition of constant and
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plasma is initiated by adding highly purified a-thrombin. The
test can be used for any direct thrombin inhibitor. The
relationship between the time of coagulation and the con-
centration of dabigatran is linear. Themost accurate is a direct
calibration by lyophilized dabigatran standard, the calibration
by hirudin is less accurate [12].
Ecarin Clotting Time (ECT) is specific to the measurement of
thrombin generation. The trigger is snake venom Ecarin
activation of prothrombin and generation of meizothrombin,
an unstable thrombin precursor. As the direct thrombin
inhibitors are able to inhibit meizothrombin activity similar to
that of thrombin, ECT allows direct measurement of their
efficacy. A linear relationship between ECT and plasmatic
concentrations of direct of thrombin inhibitors was documented
both in healthy volunteers and patients. ECT ratio of 2–4 was
found after administration of 150mg dabigatran b.i.d. Although
clinical experience favours ECT before APTT for the evaluation of
the effect of direct thrombin inhibitors, its use is rather limited
to research purposes due to the lack of wide availability of the
standardized and easy-to-use commercial kits [12].
Prothrombinase-induced clotting test (PiCT) [13,14] is used for
monitoring the efficacy of fondaparinux, dabigatran and rivar-
oxaban, this test was also used for the monitoring of activity of
heparin, low molecular heparins or hirudin for many years.
PiCT (Pentapharm, Basel, Switzerland) is an assay sensitive
to the inhibitors of factor Xa and factor IIa. The test is based on
the addition of factor Xa and the snake venom RVV (Russell
Viper Venom factor V activator) with a specific activation of
factor V and phospholipids in the platelet-poor plasma. The
mixture is recalcified after incubation and time to coagulation
is measured. It is highly sensitive and linearly proportional for
unfractionated heparin, low molecular weight heparins, hir-
udin and argatroban. Fondaparinux has non-linear response.
Parenteral direct thrombin inhibitors hirudin, lepirudin,
bivalirudin may be monitored using APTT, ECT or diluted
thrombin time (Hemoclots) (sampling is required 4 h after












Fig. 2 – LTA measures the penetration of light during the
platelet aggregation in plasma. The platelet poor plasma
(PPP) and platelet rich plasma (PRP) after stimulation by
activator (arachidonic acid, collagen, ADP, ristocetin,
epinephrine, cationic propylgalate, etc. are evaluated).3. Monitoring of the antiplatelet treatment
Antiplatelet treatment is recently undergoing very rapid
development, and today two new drugs are registered and
clinically available – in addition to the classic ones. This could
allow greater individualization of the antiplatelet treatment.
Indications and dosage of the antiplatelet treatment so far
is based rather on the standard dose according to the clinical
diagnosis than on controlled strategy determined in accor-
dance with individually measured efficiency. Treatment with
most commonly used antiplatelet drugs – acetylsalicylic acid
and clopidogrel – may, however, be from different reasons
ineffective in considerable proportion of the patients.
High residual on-treatment platelet reactivity is associated
with a higher incidence of thrombotic complications [15–17]
and on the contrary, there is also a laboratory documented
boundary of low aggregability with increased incidence of
bleeding complications [17].
Nevertheless, the evidence that the assessment of the
laboratory efficiency and consequent amendment of antiplatelettreatment would improve clinical outcome, is still scarce: the
study of Bonella and coworkers suggests that using the VASP it
was possible to document that 25% of the patients had even
after treatment with prasugrel persistent high platelet reactivity
associated with the deterioration of prognosis [18]. The intro-
duction of new and more effective antiplatelet drugs – prasugrel
and ticagrelor – to the clinical testing and practice, however, led
to the initiation of new multicentral randomized studies, which
compare the routine administration of newer more effective
drugs with a strategy of therapy escalation only in patients with
persistent high residual platelet reactivity. Such studies are
ongoing, like the ARCTIC study, in which patients are rando-
mized either to routine prasugrel or to the determination of the
residual platelet reactivity and the change of clopidogrel for
prasugrel only in patients with high residual platelet reactivity.4. Evaluation of platelet aggregability
Light transmission aggregometry (LTA), VerifyNow (turbidi-
metric optical detection system) and MULTIPLATE (multiple
electrode impedance aggregometry) are currently considered to
be the only reproducible, reliable, and prognostically relevant
methods for the evaluation of platelet aggregability [16].
LTA assesses the light transmittance during aggregation in
platelet poor plasma (PPP) and platelet rich plasma (PRP) after
stimulation by an activator (arachidonic acid, collagen, adeno-
sindiphosphate, ristocetin, epinephrine, cationic propylgalat,
etc.) (Fig. 2). The results are expressed as the maximum
aggregation (AU), the rate of the aggregation (AU/min or %/
min) or as the area under the curve (AUnmin). For patients on
antiplatelet treatment the result is expressed as a percentage of
platelet aggregability from the values without treatment [19]:
ð1residual aggregation=baseline aggregationÞ  100
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(high concentration up to 1 mM), depend on the formation of
endogenous thromboxane and assess the ability of ASA to block
the COX-1 pathway with subsequent inhibition of thromboxane
A2 (TXA2) formation. Because even complete inhibition of COX-1
activity may be bypassed via few other platelets activating
pathways, less specific functional tests can detect high platelet
reactivity even when COX-1 is completely blocked [20,21]. Less
specific activators, such as collagen, ristocetin, epinephrine or
cationic propylgalat assess therefore also the pathway indepen-
dent of COX-1 effects of ASA. An increased turnover of platelets,
transitional expression of COX-2 in the newly formed platelets or
extra-platelet TXA2 resources may result in an increased platelet
reactivity during the ASA treatment [22].
The lack of suppression of platelet function during treatment
is associatedwith a variety of causes, including non-compliance,
insufficient dosage, poor absorption from the gastrointestinal
tract, interactions with other drugs or some predefined genetic
polymorphisms.
Increased platelet reactivity is more common in patients
with acute coronary syndrome [23] and is related to an
adverse outcome [15]. It may be related to the elevatedFig. 3 – VerifyNow assesses the changes in light penetration
after aggregation of activated platelets to the particles
(beads) covered with fibrinogen.
Fig. 4 – The MULTIPLATE system is based on the principle that t
and subsequently increase the electrical resistance measured bmarkers of inflammation [15,24,25], or to the increased
activity of the tissue factor [26].
VerifyNow is used to evaluate the effect of antiplatelet
therapy by ASA, thienopyridines (clopidogrel, prasugrel, ticlo-
pidin, etc.), and GP IIb/IIIa inhibitors (abciximab, eptifibatide)
(Fig. 3). VerifyNow Aspirin Test – the activator is arachidonic
acid, result is expressed in Aspirin Reaction Units (ARU), the
cut off value is usually 550 ARU, when valuesZ550 ARUmean
normal aggregability, while values o550 mean adequate
platelets inhibition by ASA. This test cannot be performed in
patients treated with other antiplatelet drugs such as clopido-
grel, prasugrel or inhibitors of GP IIb/IIIa receptor.
VerifyNow P2Y12 test – ADP is used as an activator, the test
is focused on the evaluation of platelet aggregability in
patients already treated with clopidogrel (TEST). Therefore
aggregation after modified activator of thrombin receptor –
iso-TRAP (Thrombin Receptor Activating Peptide) – is used as
a control value in the reference channel (BASE). The test
result is given as the absolute P2Y12-Reaction-Units (PRU) and




VerifyNow GP IIb/IIIa test – uses iso-TRAP (Thrombin
Receptor Activating Peptide) as an activator, the values are
given in Platelet Aggregation Units (PAU).
MULTIPLATE evaluates the platelets function in whole blood.
Platelets aggregate on metal sensors and increase electrical
resistance measured between the pair of sensors (Fig. 4).he platelets aggregate at the surface of the metallic sensors
etween two of these sensors.
Table 4 – Cut-off values for MULTIPLATE (AUC ¼ area
under the curve, U ¼ unit, HS ¼ high sensitivity – sensi-





ASPItest (arachidonic acid, 15 mM) 74–136 30
ADPtest (adenosidiphosphat 0.2 mM) 53–122 50
ADPtest HS (ADP 0.2 mM sensitized by
prostaglandin E1)
31–107 25
TRAPtest (thrombin receptor activating
peptide, 1 mM)
94–156 30
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of ASA, ADP inhibitors and GP IIb/IIIa inhibitors, respectively.
For ASPItest – activator is arachidonic acid, cut-off values
for sufficient blockade of platelet by ASA is r50 U, values
above 50 U mean ineffective treatment by ASA (Table 4).
ADPtest is suitable for the assessment of treatment by
clopidogrel, ticagrelor, prasugrel or ticlopidin, cut-off value
for sufficient blockade is r45 U, values above 45 U mean
ineffective treatment. The initial experience suggests that the
evaluation of the effect of the new ADP inhibitor ticagrelor
may need a different cut-off values and a higher dose of ADP –
i.e. 0.6 mmol/l.
TRAPtest evaluates the effect of treatment by GP IIb/IIIa
inhibitors, ASA and inhibitors of ADP, the valuesr60 U indicate
sufficient blockade, values above 60 U mean ineffective treat-
ment.
Determination of residual platelet reactivity during antiplatelet
treatment cannot be regarded as a test for the occurrence of
thrombosis in the arterial system (such as troponin is themarker
of myocardial necrosis), but it is a test showing an increased risk
of thrombotic complications (such as, for example, hyperlipo-
proteinemia is a risk factor for the atherosclerosis development
and progression). The prerequisites to arterial thrombosis are
usually both an increased residual platelet reactivity and a
substrate like non-endothelised stent struts, an atherosclerotic
plaque rupture, etc. Available data indicate that sufficient
suppression of platelet reactivity reduces to a minimum the risk
of arterial thrombotic complications.
We documented good short-term reproducibility of the
platelet function tests, in the medium and long term
horizons, however, the results may be influenced by a whole
series of other variables, it is therefore warranted to repeat
the test in the course of the time [27].Acknowledgements
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